Publikationen in Zusammenarbeit mit Forschern von University of Pennsylvania (7)

2024

  1. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 184, pp. 168-177

2022

  1. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

2020

  1. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Obstetrical and Gynecological Survey

  2. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

    Gynecologic Oncology, Vol. 157, Núm. 2, pp. 379-385

2019

  1. Niraparib in patients with newly diagnosed advanced ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2391-2402

2013

  1. Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: An individual patient data meta-analysis

    International Journal of Radiation Oncology Biology Physics, Vol. 87, Núm. 4, pp. 690-696

  2. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: An international individual patient data meta-analysis

    International Journal of Radiation Oncology Biology Physics, Vol. 85, Núm. 2, pp. 444-450